Expression of nerve growth factor receptor mRNAs and clinical response to retinoic acid in neuroblastoma.
Four children with advanced or relapsed neuroblastoma were treated with oral 13-cis-retinoic acid 0.75 mg/kg/day. Clinical response to retinoic acid was noted only in the two children with tumors coexpressing trk protooncogene mRNA, encoding an essential part of the nerve growth factor (NGF) high affinity receptor, and low affinity NGF receptor gene (LNGFR) mRNA. Clinical stage or age, plasma neuropeptide Y, tumor DNA ploidy and N-myc amplification did not as accurately predict response to retinoic acid as NGF receptor mRNAs. In vitro data have shown that retinoic acid up regulates LNGFR expression and NGF sensitivity via interaction with specific regulatory elements in the LNGFR gene promoter. We hypothesize that part of the therapeutic effect of retinoic acid in neuroblastoma in vivo may be exerted via increased NGF receptor expression and NGF sensitivity. Analysis of trk and LNGFR mRNA may be useful to predict clinical response to retinoic acid in these children.
Kogner
P
P
Department of Pediatrics, Karolinska Hospital, Stockholm, Sweden.
Barbany
G
G
Persson
H
H
Söderhäll
S
S
Ahström
L
L
Björk
O
O
D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D016259:Genes, myc; D006801:Humans; D008297:Male; D009447:Neuroblastoma / Q000097:blood / Q000188:drug therapy*; D009478:Neuropeptide Y / Q000097:blood; D011003:Ploidies; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D017475:Receptors, Nerve Growth Factor / Q000378:metabolism*; D016896:Treatment Outcome; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use*
D004273:DNA, Neoplasm; D009478:Neuropeptide Y; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D017475:Receptors, Nerve Growth Factor; D014212:Tretinoin